From INSERM U439, 34090 Montpellier, France and
¶ INSERM U478, Faculté de Médecine Xavier Bichat,
BP416 75870 Paris Cedex 18, France
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Limited proteolysis experiments were performed to
study conformation changes induced by ligand binding on in
vitro produced wild-type and I747T mutant glucocorticoid
receptors. Dexamethasone-induced conformational changes were
characterized by two resistant proteolysis fragments of 30 and 27 kDa.
Although dexamethasone binding affinity was only slightly altered by
the I747T substitution (Roux, S., Térouanne, B., Balaguer, P.,
Loffreda-Jausons, N., Pons, M., Chambon, P., Gronemeyer, H., and
Nicolas, J.-C. (1996) Mol. Endocrinol. 10, 1214-1226),
higher dexamethasone concentrations were required to obtain the same
proteolysis pattern. This difference was less marked when proteolysis
experiments were conducted at 0 °C, indicating that a step of the
conformational change after ligand binding was affected by the
mutation. In contrast, RU486 binding to the wild-type receptor induced
a different conformational change that was not affected by the
mutation. Analysis of proteolysis fragments obtained in the presence of
dexamethasone or RU486 indicated that the RU486-induced conformational
change affected the C-terminal part of the ligand binding domain
differently. These data suggest that the ligand-induced conformational
change occurs via a multistep process. In the first step, characterized
by compaction of the ligand binding domain, the mutation has no effect.
The second step, which stabilizes the activated conformation and does
not occur at 4 °C, seems to be a key element in the activation
process that can be altered by the mutation. This step could involve
modification of the helix H12 position, explaining why the conformation
induced by RU486 is not affected by the mutation.
In its inactivated form, the glucocorticoid receptor
(GR),1 a member of the
steroid receptor family (1-4), is part of a large heterooligomeric
complex that includes hsp90 and other heat shock proteins (5). This
heterocomplex is required to maintain GR in a conformation appropriate
for ligand binding and to prevent GR from binding to DNA (6, 7).
Binding of the specific hormone induces a cascade of different
molecular events, leading to an activated GR that can, after DNA
binding, regulate gene transcription by interacting with the
transcriptional machinery. Transcriptional activation is achieved
through activation functions with the major transactivation function
AF-1 located within the N-terminal domain and the weak
ligand-dependent transactivation function AF-2 in the
C-terminal hormone binding domain (for reviews and references see Refs.
8 and 9). The AF-2 activation domain, which is part of the larger AF-2
and conserved in the nuclear receptor superfamily, was shown to be
essential for transactivation (10-14). Comparison of ligand binding
domain crystal structures of the unliganded retinoid-X receptor Previous studies have shown that ligand-induced conformational
change is involved in the activation of various nuclear receptors (19-22). This structural modification converts the entire LBD of various nuclear receptors to a more compact structure that is less
accessible to proteases (19, 22-34). A different conformational change
induced by antihormones that affects the C-terminal end of the receptor
was previously reported (20, 22, 25, 26). Antagonist-induced
proteolysis-resistant fragments obtained for various nuclear receptors
are smaller than those obtained in the presence of agonists (19, 20,
22, 25, 29, 35) or less resistant to proteolytic degradation (23).
Most GR mutations described in the LBD involve a decrease in ligand
binding affinity (8, 36-41). In contrast, we recently described a
mutant (substitution of human GR isoleucine 747 by a threonine,
hereafter referred to as I747T) with no significant alteration of
ligand binding affinity but which required higher dexamethasone
concentrations than the wild-type GR (wt GR) to induce reporter gene
transactivation (42). This mutation is located just before the H12
helix. It has been proposed that modification of helix H12 positioning
upon agonist binding generates a surface for interactions with various
coactivators, whereas the conformation of the apo-receptor and the
antagonist-receptor complex does not permit these interactions (for
reviews and references see Refs. 43 and 44).
As the I747T mutation alters the transactivation function of the
receptor without modifying ligand-receptor interactions, we assumed
that the dynamics of the transconformation process were modified. In
this study, we used partial proteolysis to analyze the conformation of
the wt GR and the mutant I747T before and after agonist and antagonist binding.
Materials--
Dexamethasone and trypsin (type XIII) were
purchased from Sigma. RU486 was a gift from Roussel Uclaf (Romainville,
France). RainbowTM 14C-methylated protein
molecular weight markers were obtained from Amersham Pharmacia Biotech
as well as the enhanced chemiluminescence (ECL) Western blotting
detection reagents (Les Ulis, France). L-[35S]Methionine (>1000 mCi/mM)
was obtained from ICN; TNTT7 reticulocyte lysate system and
RNasin ribonuclease inhibitor were from Promega (Charbonnieres,
France), and ENTENSIFY was from NEN Life Science Products. The GR
polyclonal antibody P-20 was purchased from Santa Cruz Biotechnology
Inc. (TEBU, Le Perray en Yvelines, France).
Plasmids--
Plasmid wt human GR containing the open reading
frame of the wild-type GR as well as the Coupled in Vitro Transcription and Translation--
Expression
plasmids (pSG5-GR) were transcribed and translated with the
TNTT7-coupled reticulocyte lysate system in the presence of
[35S]methionine (1000 Ci/mmol, Amersham Pharmacia
Biotech) according to the manufacturer's instructions for 1 h at
30 °C.
Limited Proteolysis--
Pretreatment of labeled translation
mixtures was performed for 10 min at room temperature with vehicle or
ligand (conserved in ethanol, dried, and re-suspended in 50% (v/v)
PEG300, 1% of the total reaction volume). Limited trypsinization was
performed by the addition of 1 µl of protease solution (trypsin
dissolved in water) to aliquots (5 µl) of the hormone-treated
receptor mixture (final trypsin concentrations 5 to 100 µg/ml).
Incubations with protease were conducted for 10 min at room temperature
and stopped by cooling in ice. 20 µl of SDS sample buffer was added,
and the samples were boiled for 5 min. The proteolysis products were
separated on a 0.75-mm thick SDS 12.5% polyacrylamide gel. After
electrophoresis, the gels were fixed in methanol (30%, v/v), acetic
acid (10%, v/v), treated with ENTENSIFY, and vacuum-dried at 70 °C
for 45 min. Autoradiography was performed overnight.
Sucrose Gradient Centrifugation--
In vitro
synthesized 35S-wt GR or I747T were incubated for 10 min at
20 °C with 10 Immunoblotting--
A limited proteolysis experiment was
conducted with the in vitro 35S-synthesized wt
GR proteins. After SDS/polyacrylamide gel electrophoresis (10% gel),
the protein fragments were electrophoretically transferred to
nitrocellulose. Western blotting was performed using the rabbit polyclonal antibody P-20 directed against a peptide corresponding to
amino acids 750-769 mapping at the C-terminus of the human GR (Santa
Cruz Biotechnology, Inc). Immunoreactive proteins were visualized using
enhanced chemiluminescence Western blotting detection reagents
(Amersham Pharmacia Biotech).
Bioimaging Analysis on Fujix Bas 1000PC--
Quantitative
analysis of proteolytic fragments was performed by gel scanning with a
Fujix film imaging plate. Photo-stimulated photon for each band were
determined on a Fujix Bas 1000PC and expressed as a percentage of the
full-length receptor photo-stimulated photon.
Higher Dexamethasone Concentrations Are Required to Protect I747T
GR against Proteolysis Than for the Wild-type GR--
To analyze
changes in wt and I747T GR conformation induced by dexamethasone
binding, in vitro produced receptors were incubated with
10
Further proteolysis experiments were performed using various
dexamethasone concentrations (10 A Temperature-dependent Step in the Transconformation
Process Is Altered by the I747T Mutation--
In vitro
activation of GR is a temperature- and ligand-dependent
process (46). Nevertheless, in nonactivating conditions, ligand binding
to the receptor appears sufficient to induce a structural modification
detectable by proteolysis (22, 47). We thus compared the proteolytic
pattern of the wt and I747T GR after incubation with 10 Hsp Release Is Not Altered by the I747T Mutation--
It was
previously reported that transformation of GR by ligand binding into a
transcriptionally activated form is accompanied by the release of Hsp
from the receptor (48, 49). We postulated that alteration of Hsp
release from I747T could account for the shifted ligand-induced
conformational change. To investigate this hypothesis, we performed a
ligand-independent removal of Hsp using high NaCl and ATP
concentrations, a treatment known to remove Hsp from receptors (50),
and analyzed the sedimentation profile of the mutant and wt GR on
sucrose gradient. NaCl and ATP treatment was efficient to remove Hsp
from the wild type and mutant GR as evidenced by the decrease in the
sedimentation coefficient for both receptors (9-10 S versus
6-7 S) (Fig. 4).
When proteolysis experiments of liganded wt and mutant GR were
performed after ATP/NaCl treatment, protection of the fragments was not
markedly affected (Fig. 5, A
and B, respectively; compare lanes 2-3 with
lanes 5-6). Taken together, these results showed that hsp
release was not altered by the mutation and that hsp dissociation was
not involved in the shifted ligand-induced conformational change.
Conformational Change Induced by RU486 Binding Is Not Affected by
the I747T Mutation--
Previous experiments showed that RU486
presents a similar antagonistic activity with wt and I747T GR (42). To
explore the conformation of I747T after RU486 binding, we performed
proteolysis experiments on translated wt or I747T receptors treated
with 10
At 10 µg/ml trypsin concentration, a 30-kDa fragment was obtained
(Fig. 6, lanes 2 and 7). Proteolysis with 25 µg/ml trypsin (lanes 3 and 8) decreased the
amount of the 30-kDa fragment and increased the amount of the 27-kDa
fragment. These two main species were split off into two slightly
different additional fragments (~29.5 and 27.5 kDa). At 50 µg/ml
trypsin concentration (lanes 4 and 9), these
resistant fragments were obtained as well as an additional 25-kDa
fragment, with the smallest species (27 and 25 kDa) being the most
abundant. At higher trypsin concentration (100 µg/ml, lanes
5 and 10), the 25-kDa fragment was the main fragment.
These proteolysis fragments, except for the 25-kDa species, were
recognized by the antibody directed against the 750-769 amino acid
sequence (data not show). After treatment with various RU486 concentrations (10 In this study, we investigated the involvement of ligand-induced
conformational changes in the previously described shifted transcriptional activity of the GR mutant I747T. This mutation drastically alters the ligand specificity for transactivation but not
for binding (42).
Conformational changes observed after ligand binding are assumed to
induce a decrease in the accessibility of cleavage sites within the
receptor molecule, which can be easily detected by modifications of
proteolysis patterns. In agreement with previous reports (20, 34, 47),
we found that dexamethasone-induced conformational changes of the
wild-type GR (wt) were characterized by two resistant proteolytic
fragments (30 and 27 kDa), whose respective intensities were related to
the trypsin concentration used in the assay. We also found that
protection of these fragments was dependent on the dexamethasone
concentration used (Fig. 2). At 10 Taken together these data suggested that acquisition of a
transcriptionally efficient conformational change is a multistep process with a dynamic dimension (Fig.
7). An intermediary complex would first
be generated by ligand binding (Fig. 7A, step 1). The second step, occurring rapidly at room temperature, would convert
the intermediary complex into a more stable conformational state,
corresponding to the transcriptionally efficient conformation (step
2). We hypothesized that the activated receptor could be stable enough to exist in a transient unliganded activated form (step
3). Taking into account the observation that the I747T
substitution has little effect on affinity, we propose that this
substitution does not affect intermediary complex formation (Fig.
7B; step 1) but alters the stability of the
activated receptor conformation. High ligand concentrations are
required to permit a rapid ligand reassociation to the unstable
activated receptor and so permit conservation of a sufficient
concentration of efficient conformation to transactivate.
Interestingly the Tyr-537 mutation within the ER (corresponding to
Phe-749 for human GR) confers constitutive activity (54), probably by
affecting the specific stabilization of active aporeceptor conformation
(55). Conversely, a destabilizating effect of mutation I747T in GR
might induce an unstable active conformation. Moreover, the mutation
occurring at the same position in the androgen receptor (Val-889) in
the case of nearly complete androgen insensitivity (56, 57) could also
imply destabilization of the active conformation, because this mutant
showed a slight increase in its dissociation rate, with a drastic
modification of EC50 in transactivation assays. As
mentioned by the authors, an increase in denaturation could also be
involved because dissociation of the ligand could lead to rapid
receptor denaturation because of instability of the activated
conformation. High ligand concentrations, by increasing the ligand
association rate, could protect against receptor denaturation and are
required to obtain full activity.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
with liganded retinoic acid receptor
, liganded thyroid hormone
receptor
, and liganded estrogen receptor (ER) suggests that ligand
binding triggers folding back of the H12
-helix, which contains the
AF-2 activation domain, whereas in aporeceptors this helix protrudes
from the ligand binding domain (LBD) core (15-18).
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
A/B wt GR and the mutant
I747T have been previously described (42). Plasmids containing coding
sequences of mouse GR (pSV2Wrec) and three mutants (M758A/L759A, E761A, and I762A/I763A) were obtained from the laboratory of Professor M. G. Parker (11). To place them under the control of the T7 promoter, XbaI-BglII fragments containing the
coding sequences were excised, blunted, and subcloned into the blunted
EcoRI site of pSG5 (45).
7 M dexamethasone followed by
an additional incubation with ATP (10 mM) and NaCl (0.4 M) for 15 min (activation step). An equal volume of water
was added for the unactivated controls. Samples were layered on top of
a 5-20% sucrose gradient prepared in TEG buffer (20 mM
Tris/HCl, pH 7.4, 1 mM EDTA, and 10% (v/v) glycerol). Gradients were centrifuged in a VTi 65.2 rotor at 4 °C for 2 h at 65,000 rpm. Aldolase (see Fig. 4, A, 7.9 S), bovine serum
albumin (see Fig. 4, BSA, 4.6 S), and myoglobin (see Fig. 4,
M, 2 S) were used as external sedimentation markers.
Three-drop fractions were collected by piercing the bottom of each
tube. The collected fractions were analyzed on a 7.5% (w/v) acrylamide
gel and subjected to autoradiography. The band corresponding to the
94-kDa fragment was densitometrically scanned by image analysis
(Optilab, Graftek, France) and quantified.
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
5 M dexamethasone, then limited
trypsinization was performed, and the resulting proteolysis fragments
were analyzed (Fig. 1). At low trypsin
concentrations (5 and 10 µg/ml; lanes 2-3, respectively), similar proteolysis patterns were obtained for wt GR (Fig.
1A) and I747T GR (Fig. 1B) with a main 30-kDa
fragment. At 25 µg/ml trypsin concentration (lane 4), 2 fragments, 30- and 27-kDa, were obtained for both receptors. At 50 µg/ml trypsin concentration (lane 5), the abundance of the
30-kDa species decreased to the benefit of 27-kDa species. The 27-kDa
fragment became predominant for both receptors. The 30- and 27-kDa
fragments contained all or part of the LBD, as previously reported for
various nuclear receptors because they were also obtained with a
A/B-GRwt and were recognized by a specific antibody directed against
the C-terminal region of this domain (data not shown).
View larger version (45K):
[in a new window]
Fig. 1.
Limited trypsin digestion of wt and I747T
receptors. In vitro produced 35S-wt GR
(A) or 35S-I747T (B) were
preincubated with 10 5 M dexamethasone for 10 min at 20 °C before digestion with increasing trypsin concentrations
(0, 5, 10, 25,and 50 µg/ml; lanes 1, 2,
3, 4, and 5, respectively).
Autoradiograms of each samples, denatured and analyzed on a 12.5%
polyacrylamide gel, are shown. The migration of molecular weight marker
is indicated on the left, and resistant proteolysis fragments are
indicated by asterisks on the right.
9 to 10
5
M), and the intensities of the proteolytic fragments were
quantified. Values obtained for both fragments were added and presented
as a percentage of the intensity of the full-length receptors (Fig. 2). At 5 µg/ml trypsin concentration
(Fig. 2A), fragments generated from wt GR had the same
intensity as fragments generated from I747T GR, indicating that at this
trypsin concentration both receptors were similarly protected. Because
more than half of the methionine residues were located in the
C-terminal part of the receptor, we assumed that at
10
7-10
6 M dexamethasone
concentration 100% of both GRs would be converted into a more compact
structure. These results are consistent with the similar dexamethasone
affinities reported for wt GR and I747T (42). At higher trypsin
concentrations (10, 25, and 50 µg/ml; Fig. 2, B,
C, and D, respectively), the maximal level of
protection for the wt GR was within the same order of magnitude and was
reached regardless of the trypsin concentration used at the same
dexamethasone concentrations (10
7-10
6
M). In contrast, for the mutant at these trypsin
concentrations (10, 25, and 50 µg/ml. Fig. 2, B,
C, and D, respectively), there was a lower
protection level for both fragments. I747T required higher
dexamethasone concentrations to achieve the same extent of protection
as noted for the wt GR. Because the affinity for dexamethasone was not
drastically affected by the mutation, these results suggested that this
mutation could affect the transconformational process induced by
dexamethasone binding.
View larger version (32K):
[in a new window]
Fig. 2.
Effects of dexamethasone
(Dex) concentrations on limited trypsin digestion of
wt GR and I747T. In vitro translated wt GR and I747T
were preincubated with various dexamethasone concentrations (0, 10 9-10
5 M) for 10 min at
20 °C before digestion with 5 µg/ml (A), 10 µg/ml
(B), 25 µg/ml (C), and 50 µg/ml
(D) of trypsin. Autoradiograms of each samples, denatured
and analyzed on a 12.5% polyacrylamide gel, are shown at the top of
each graph. wt GR (lanes 1-6) and I747T
(lanes 7-12) were incubated with 0 (lanes
1 and 7), 10
9 M (lanes
2 and 8), 10
8 M (lanes
3 and 9), 10
7 M (lanes
4 and 10), 10
6 M (lanes
5 and 11), and 10
5 M
(lanes 6 and 12) dexamethasone. Each band was
scanned and analyzed on a phosphoimaging analyzer (Fujix Bas 1000PC).
The relative photostimulated luminescence of wt GR- and
I747T-resisting fragments are expressed as the percentage of
photo-stimulated photon value of the full-length GRs (PSL)
and plotted as a function of dexamethasone concentration. 30- and
27-kDa fragments are represented as associated wt GR-resisting
fragments (
) or I747T-resisting fragments (
).
7
or 10
5 M dexamethasone concentrations at
0 °C, a temperature that inhibits the activation process, or at room
temperature. This incubation was followed by trypsin treatment
performed for 1 h at 0 °C, conditions in which the unliganded
wt or I747T GR were totally digested. The percentage of 30- and
27-resisting fragments obtained for vehicle alone, dexamethasone × 10
7 M, or dexamethasone × 10
5 M are given in Fig.
3. The maximum level of protection
(i.e. maximal intensity of the 30- and 27-kDa fragments) was
obtained for the wt GR after incubation with a 10
5
M dexamethasone concentration at 0 °C or with a
10
7 M concentration at 20 °C (Fig.
3A). In contrast, the maximum level of protection for I747T,
similar to that obtained with wt GR, was reached only after incubation
with a 10
5 M dexamethasone concentration at
20 °C (Fig. 3B) (45 ± 5% versus 50 ± 4%, respectively). These results suggest that a step in the ligand-induced conformational change occurring at room temperature was
drastically altered. The similar level of protection obtained for both
receptors at 10
5 M suggests that higher
dexamethasone concentrations could maintain a protected conformation
even in the absence of any activation process.
View larger version (29K):
[in a new window]
Fig. 3.
Limited digestion of wt GR or I747T by
50 µg/ml trypsin with or without activating
process. In vitro translated wt GR (A) or
I747T (B) were preincubated on ice (0 °C) or at
room temperature (20 °C) for 10 min in the presence of vehicle alone
(Control) or dexamethasone (Dex) × 10 7 M or 10
5 M
before trypsin digestion (50 µg/ml) for 1 h at 0 °C.
Quantification of each protected fragment, determined as in Fig. 1, is
expressed in percentage of the undigested receptor. A sum of 30 (shadow box)- and 27 (open box)-kDa- resisting
fragments are represented for each sample. Data are expressed as means
±S.D. of three independent experiments. *, significantly
(p < 0.05) different from measurements at
10
5 M dexamethasone by Student's
t test.
View larger version (27K):
[in a new window]
Fig. 4.
Sucrose gradient analysis of activated and
nonactivated wt GR and I747T. In vitro synthesized
35S-wt GR or -I747T was incubated for 10 min at 20 °C
with 10 7 M dexamethasone followed by an
additional incubation with ATP (10 mM) and NaCl (0.4 M) for 15 min (open circle). An equal volume of
water was added for the unactivated controls (filled
circle). 90-µl aliquots were layered on top of a 5-20% sucrose
gradient prepared in TEG buffer. Gradients were centrifuged for 2 h at 65,000 rpm in a VTi 65.2 rotor at 4 °C. The collected fractions
were analyzed on a 7.5% (w/v) acrylamide gel and subjected to
autoradiography. The band corresponding to the 94-kDa fragment was
densitometrically scanned and quantified. Results are given as signal
intensity expressed in arbitrary units as a function of the Rf
(RF). The sedimentation markers are indicated for aldolase
(A, 7.9 S), bovine serum albumin (BSA, 4.6 S),
and myoglobin (M, 2 S).
View larger version (33K):
[in a new window]
Fig. 5.
Proteolysis analysis of activated and
nonactivated wt GR and I747T. Translated wt GR (A) or
I747T (B) were incubated for 10 min at room temperature with
10 7 M dexamethasone. Treatment with ATP (10 mM) and NaCl (0.4 M) was performed for 15 min
(lanes 4-6) to induce ligand-independent dissociation of
heat shock proteins before limited digestion by the indicative
concentration of trypsin and analyzed as described under
"Experimental Procedures." Positions of resistant proteolysis
fragments are indicated by asterisks on the right, and those
of molecular mass markers are indicated on the left.
7 M RU486 concentration. A similar
proteolysis pattern was obtained for both receptors (Fig.
6).
View larger version (25K):
[in a new window]
Fig. 6.
Limited digestion of RU486-bound I747T
GR. In vitro synthesized 35S- wt GR
(lanes 1-5) and I747T (lanes 7-10) were
incubated with a RU486 concentration of 10 7 M
and subjected to limited trypsinization by the indicative levels of
trypsin. The migration of molecular weight marker is indicated on the
left, and resistant proteolysis fragments are indicated by
arrows on the right.
9-10
6 M),
quantification of main fragments (30-, 27- and 25-kDa) led to
indistinguishable protection curves for wt GR and I747T (data not
shown), regardless of the trypsin concentrations applied. RU486
concentrations required to obtain half-maximal protection of each
fragment are reported in Table I. The
same RU486 concentration (
10
8 M) was
sufficient to convert wt GR and I747T to a trypsin-resistant form.
These results led us to conclude that the RU486-induced conformational
change was not affected by the mutation and differed from that induced
by an agonist.
RU486 concentration required to observed half-maximal protection of
each resisting fragment for wt GR and I747T
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
7-10
6
M, the wt GR was totally converted to a resistant
conformation. Although dexamethasone binding was sufficient to protect
the mutant I747T from low trypsin concentration digestion (5 µg/ml;
Fig. 2A), a 25-50-fold higher dexamethasone concentration
was required to protect the 30- and 27-kDa fragments against high
trypsin levels (Fig. 2, B, C, and D).
The shift in the dose-response curve for proteolysis protection of
I747T was in agreement with the shift in the transcriptional response
curve previously reported (42). It is important to note that at high
dexamethasone concentrations, similar protection and transactivation
activity levels were reached for I747T and wt GR (42). After cortisol
binding, only submaximal protection of these fragments was obtained
with the mutant (data not shown), in accordance with the results of a
previous study showing submaximal stimulation of a reporter gene (42).
It should be also noted that I747T presented an affinity for
dexamethasone or cortisol within the same order of magnitude as that
obtained for the wt GR (42). Moreover, GR proteins synthetized with
rabbit reticulocyte lysate had the same binding affinity as the native protein expressed in cells (51-53). This suggests that the relative affinity of the receptor for the ligand was not directly responsible for the shifted protection curve. Similarly, AF-2 activation domain mouse GR mutants, which are unable to transactivate at concentrations up to 10
5 M dexamethasone without
modification of ligand binding affinity (11), were also unable to
generate the same proteolysis pattern as the wt (data not shown). Taken
together, the data presented here indicated that the ability of GR to
activate transcription was not only dependent on its ability to bind
its ligand, i.e. it was also correlated with the ligand
binding-induced conformational change of GR characterized by increasing
protection of the 30- and 27-kDa species at high trypsin
concentrations. This resistance to trypsin digestion might be relevant
to a stabilization of an efficient conformation by high dexamethasone
concentrations. As a similar protection level was obtained for I747T
and the wt GR at 0 °C, it is likely that a step in the
ligand-induced conformational change occurring at room temperature and
probably associated with the stabilization of the conformation was
impaired or drastically modified for the mutant. Moreover, our
experiments showed that no impaired hsp90 dissociation was involved in
the shifted protection curve for the mutant. As reported for the
progesterone receptor (20) and the mineralocorticoid receptor (23), the
conformational change might have occurred within the heterooligomeric
structure, thus inducing hsp release, and is not a consequence of an
altered hsp dissociation.
View larger version (19K):
[in a new window]
Fig. 7.
An equilibrium model for
hormone-dependent conformational changes. In the
absence of hormone, receptors exist as an apo-receptor complex
associated with hsp90 and other proteins in a conformation permissive
for hormone binding but weakly resistant to trypsin digestion.
A, after hormone binding, the wt GR is immediately
transformed via an intermediary complex (step 1) to an
activated receptor with a conformational change that could trigger
modification of helix H12 position (step 2). This
conformational change stabilized the activated form and thus increased
the efficiency of protection and transactivation. This activated state
of the receptor could be stable enough to persist even after ligand
dissociation (step 3) before degradation or return to an
unactivated aporeceptor complex. B, with I747T, the rate of
transformation of the intermediary complex, normally obtained after
ligand binding (step 1) to an activated holoreceptor, might
be decreased (step 2). Moreover, after ligand dissociation
(step 3), the activated aporeceptor might be less stable and
so might persist for less time than the wt.
Contrary to that observed with dexamethasone, the RU486 binding-induced conformation characterized by three main resistant fragments (30-, 27-, and 25-kDa species) was not affected by the mutation. Western blot experiments using a specific antibody recognizing a C-terminal epitope indicated that the RU486-induced conformational change affected the C-terminal tail of the GR differently (data not shown). Similar results were recently reported with rat GR (29). The H12 helix, which contains this region (for reviews and references, see Ref. 58), lies outside the LBD body after RU486 binding, rendering it accessible to proteases. A recent crystallographic analysis of the ligand binding domain of ER in the presence of the antagonist raloxifen revealed that H12 helix can adopt a distinct antagonist position (18). Because (i) the position of the C-terminal tail of the LBD was the major difference between dexamethasone- and RU486-induced conformational changes and (ii) the mutation altered only the structural modifications induced by agonist binding, we postulated that the second step of the agonist conformational change process especially involves the positioning of the H12 helix. Mutation of isoleucine 747, which is located in the loop between helix H11 and H12, might alter the displacement of H12. It has been postulated that folding back of the H12 helix after agonist binding generates a surface for interactions with various co-activators correlated with a functional AF-2 activity (for reviews and references, see Refs. 43 and 44). These co-activators could act, as proposed by Henttu et al. (59), as bridging proteins between the receptor and the basal transcriptional machinery, and they are likely involved in stabilization of the conformation. In contrast, most of these coactivators are unable to interact with receptors after RU486 binding (60-62), in accordance with the inactivity of AF-2 (63).
Finally, mutations in the loop between helix H11 and H12 could
specifically alter the conformation process induced by agonist binding,
probably by altering the position of H12 helix, and this positioning is
affected differently depending on the amino acids. The analysis of the
transactivation function correlated with the analysis of the receptor
sensitivity to proteolysis could be a powerful strategy to investigate
the involvement of each amino acid of the H11-H12 loop in the
ligand-induced conformational change.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Drs. H. Gronemeyer, D. Moras (Illkirch, France), and J-L Borgna (Montpellier, France) for very useful discussions. We are grateful to Dr. D. Philibert, Roussel-Uclaf (Romainville, France) for the gift of RU486. We also thank Professor M. G. Parker (London) for providing us with full-length and mutant mouse GR constructs. We also thank V. Georget for assistance in the immunoblotting experiments.
![]() |
FOOTNOTES |
---|
* This work was supported in part by INSERM and a grant from the European Community (BMH4 CT-96-0181).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Present address: Embryologic Moléculaire, Institut Pasteur, 25 rue du Dr Roux, 75724 Paris, France.
To whom correspondence should be addressed: INSERM U439, 70 rue de Navacelles, 34090 Montpellier France. Tel.: 33-467-04-37-00; Fax: 33-467-04-37-15; E-mail: nicolas{at}U439.montp.inserm.fr.
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: GR, glucocorticoid receptor; ER, estrogen receptor; LBD, ligand binding domain; wt, wild type.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|